Abstract
It is now more than 30 years since the first cold-adapted influenza viruses were developed in Russia as potential live, attenuated vaccines. In the past 15–20 years considerable experience has been gained from Russian and joint Russian-US laboratory and clinical studies with type A monovalent and bivalent vaccines prepared with genetic reassortant viruses derived from one of these cold-adapted viruses in particular, A/Leningrad/134/57. More recent experiences include use of trivalent cold-adapted vaccines with a type B component. The overall high level of safety of individual and combined vaccines in pre-school and school-aged children, with illness reductions in open field trials equivalent to that seen with inactivated vaccines, is such as to suggest that practical measures might now be justified to facilitate expansion of the use of these vaccines to other countries. It is proposed that further experimentation with the Russian cold-adapted live attenuated vaccines should be focused on issues that will relate to the public health perspective, i.e. selection of the single best candidiate type A and B vaccines for intense study using as criteria their potential for meeting licensing requirements outside Russia, and documenting the clinical protective efficacy of a single vaccine dose compared to two doses as studied until now. Resolution of these issues is important to ensure that costs for future live vaccine production, control, and utilization will be kept at lowest levels so that expanded use of live vaccines will have maximum cost-benefit and affordability. To guide those interested in these issues, examples are given of populations for whom a licensed live cold-adapted vaccine might be considered, together with indications of extra data needed to fully validate each suggested use.
Article PDF
References
Zhdanov VM. Live influenza vaccines in USSR: Development of studies and practical application. In: Kendal AP, Patriarca P (eds), Options for the control of influenza. New York: Alan R. Liss, 1986; 193–205.
Kendal AP, Maassab HF, Alexandrova GI, Ghendon YZ. Development of cold-adapted recombinant live, attenuated influenza A vaccines in the USA and USSR. Antiviral Research 1981; 1: 339–365.
Ghendon YZ, Polezhaev KV, Lisovskaya TE, et al. Recombinant cold-adapted attenuated influenza A vaccines for use in children: Molecular genetic analysis of the cold-adapted donor and recombinants. Infect Immun 1984; 44: 730–733.
Alexandrova GI, Maassab HF, Kendal AP, et al. Laboratory properties of cold-adapted influenza B live vaccine strains developed in the US and USSR, and their B/Ann Arbor/1/86 cold-adapted reassortant vaccine candidates. Vaccine 1990; 8: 61–64.
Nevedomskaya GN, Medvedeva TE, Zhikhareva AI, et al. Evaluation of the degree of attenuation of cold-adapted influenza A virus strains in CBA mice and Syrian hamsters. Voprosi Virologii 1992; 37: 37–40 (in Russian).
Klimov AE, Cox NJ, Yotov WV, et al. Sequence changes in the live attenuated, cold-adapted variants of influenza A/Leningrad/134/57 (H2N2) virus. Virology 1992; 186: 795–797.
Alexandrova GI, Polezhaev FI, Budilovsky GN, et al. Recombinant cold-adapted attenuated influenza A vaccines for use in children: Reactogenicity and antigenic activity of cold-adapted recombinants and analysis of isolates from vaccinees. Infect Immun 1984; 44: 734–739.
Alexandrova GI, Budilovsky GN, Koval TA, et al. Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: An epidemiological field trial. Vaccine 1986; 4: 114–118.
Slepushkin AN, Patriarca PA, Obrosova-Serova NP, et al. Class-specific antibody responses in school children vaccinated with an A/Brazil/11/78 (H1N1)-like recombinant influenza virus prepared from the A/Leningrad/134/57 paediatric cold-adapted donor strain. Vaccine 1988; 6: 25–28.
Slepushkin AN, Obrosova-Serova NP, Burtseva EI, et al. Comparison of live attenuated and inactivated influenza vaccines in schoolchildren in Russia, 1: Safety and efficacy in two Moscow schools, 1987/88. Vaccine 1993; 11: 323–328.
Rudenko LG, Lonskaya NI, Klimov AI, et al. Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3–14 year olds. Bull WHO 1996; 74: 77–84.
Rudenko LG, Slepushkin AN, Monto AS, et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Inf Dis 1993; 168: 881–887.
Obrosova-Serova NP, Slepushkin AN, Kendal AP, et al. Evaluation in children of cold-adapted influenza B live attenuated intranasal vaccine prepared by reassortment between wild-type B/ann Arbor/1/86 and cold-adapted B/Leningrad/14/55 viruses. Vaccine 1990; 8: 57–60.
Khan AS, Polezhaev F., Vasilijeva R, et al. Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. J Inf Dis 1996; 173: 453–456.
Rudenko LG, Arden N, Grigorieva E, et al. Safety and immunogenicity of Russian live attenuated and US inactivated trivalent vaccines in the elderly. In: Brown LE, Hampson AW, Webster RG (eds), Options for the Control of Influenza III. Amsterdam: Elsevier, 1996; 572–578.
Klimov AE and Cox NJ. PCR restriction analysis of genome composition and stability of cold-adapted reassortant live influenza vaccines. Journal of Virological Methods 1995; 52: 41–49.
Klimov AE, Egorov AY, Gushchina MI, et al. Genetic stability of cold-adapted A/Leningrad/134/47/57 (H2N2) influenza viruses: Sequence analysis of live cold-adapted reassortant vaccine strains before and after replication in children. J Gen Virol 1995; 76: 1521–1525.
Klimov AI, Rudenko LG, Egorov AY, et al. Genetic stability of Russian cold-adapted live attenuated reassortant influenza vaccines. In: Brown LE, Hampson AW, Webster RG (eds), Options for the Control of Influenza III. Amsterdam: Elsevier, 1996; 129–136.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kendal, A.P. Cold-adapted live attenuated influenza vaccines developed in Russia: Can they contribute to meeting the needs for influenza control in other countries?. Eur J Epidemiol 13, 591–609 (1997). https://doi.org/10.1023/A:1007327505862
Issue Date:
DOI: https://doi.org/10.1023/A:1007327505862